

AUTOMOTIVE INDUSTRIES WELFARE FUND



4160 DUBLIN BOULEVARD SUITE 400 | DUBLIN, CA 94568-7756
TELEPHONE (800) 635-3105 | FAX (925) 588-7121
www.aitrustfunds.org

Date: December 30, 2020

To: Participants and their Dependents in the Automotive Industries Welfare Fund (including COBRA Participants)

From: Board of Trustees, Automotive Industries Welfare Fund

This Participant Notice provides information that is VERY IMPORTANT to you and your dependents. Please take the time to read it carefully.

Clarification of Coverage for Gene Therapy

At the recent Board meeting, it was confirmed that the self-funded Plans will cover certain gene therapies that are FDA-approved. Although this is more of an interpretation of current plan language rather than a plan change, we thought it would be helpful to the Participants to outline some of the terms of coverage.

Gene therapy seeks to modify or introduce genes into a patient's body with the goal of treating, preventing or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy; introducing a new, correct copy of a gene into the body; or turning off genes that cause medical problems. Kymriah, Yescarta, Luxturna and Zolgensma have all been approved by the FDA. These may be considered as medically necessary treatment for a rare subset of patients.

All gene therapy must be preauthorized by Anthem Blue Cross (Anthem). If you do not receive Preauthorization when it is required, **the benefit payable will be reduced by \$250.** If services are subsequently determined to be not medically necessary, there will be no benefits available. Anthem will determine whether the patient meets the indications for use of the therapy. Where possible, the patient will be directed to a network provider.

Please keep this important notice with your Plan Document/Summary Plan Description (SPD) for easy reference to all Plan provisions. If you have any questions, you may call the Trust Fund Office at (800) 635-3105.

Receipt of this notice does not constitute a determination of your eligibility. If you wish to verify eligibility, or if you have any questions regarding this Plan change, please contact the Trust Fund Office.

In accordance with ERISA reporting requirements, this document serves as your Summary of Material Modifications to the Plan.

5619896v3/01158.001